Orphans Dominate New US FDA Approvals, Thanks To Rethymic, Tavneos, And Livmarli

 
• By Bridget Silverman

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

Keeping Track Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers